VALLEY FORGE, Pa.--(BUSINESS WIRE)--April 1,
2008--AmerisourceBergen Corporation (NYSE:ABC) today announced that it
plans to release its results for the Second Quarter of Fiscal Year
2008 on Wednesday, April 23, 2008 prior to the opening of trading on
the New York Stock Exchange. The Company will host a conference call
to discuss the results at 11:00 a.m. Eastern Daylight Time on April
23, 2008.
Participating in the conference call will be:
R. David Yost, President & Chief Executive Officer
Michael D. DiCandilo, Executive Vice President & Chief
Financial Officer
The dial-in number for the live call will be (612) 332-0430. No
access code is required.
The live call will also be webcast via the Company's website at
www.amerisourcebergen.com. Users are encouraged to log on to the
webcast approximately 10 minutes in advance of the scheduled start
time of the call.
Replays of the call will be made available via telephone and
webcast. A replay of the webcast will be posted on
www.amerisourcebergen.com approximately two hours after the completion
of the call and will remain available for thirty days. The telephone
replay will also be available approximately two hours after the
completion of the call and will remain available for seven days. To
access the telephone replay from within the US, dial 800-475-6701.
From outside the US, dial 320-365-3844. The access code is 917886.
About AmerisourceBergen
AmerisourceBergen is one of the world's largest pharmaceutical
services companies serving primarily the United States and Canada.
Servicing both pharmaceutical manufacturers and healthcare providers
in the pharmaceutical supply channel, the Company provides drug
distribution and related services designed to reduce costs and improve
patient outcomes. AmerisourceBergen's service solutions range from
pharmacy automation and pharmaceutical packaging to reimbursement and
pharmaceutical consulting services. With more than $66 billion in
annual revenue, AmerisourceBergen is headquartered in Valley Forge,
PA, and employs more than 11,500 people. AmerisourceBergen is ranked
#29 on the Fortune 500 list. For more information, go to
www.amerisourcebergen.com.
FORWARD-LOOKING STATEMENTS
This news release may contain certain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These statements
are based on management's current expectations and are subject to
uncertainty and changes in circumstances. Actual results may vary
materially from the expectations contained in the forward-looking
statements. The following factors, among others, could cause actual
results to differ materially from those described in any
forward-looking statements: competitive pressures; the loss of one or
more key customer or supplier relationships; customer defaults or
insolvencies; changes in customer mix; supplier defaults or
insolvencies; changes in pharmaceutical manufacturers' pricing and
distribution policies or practices; adverse resolution of any contract
or other disputes with customers (including departments and agencies
of the U.S. Government) or suppliers; regulatory changes (including
increased government regulation of the pharmaceutical supply channel);
government enforcement initiatives (including (i) the imposition of
increased obligations upon pharmaceutical distributors to detect and
prevent suspicious orders of controlled substances (ii) the
commencement of further administrative actions by the U. S. Drug
Enforcement Administration seeking to suspend or revoke the license of
any of the Company's distribution facilities to distribute controlled
substances, (iii) the commencement of any enforcement actions by any
U.S. Attorney alleging violation of laws and regulations regarding
diversion of controlled substances and suspicious order monitoring),
or (iv) the commencement of any administrative actions by the board of
pharmacy of any state seeking to suspend, revoke or otherwise restrict
the ability of any of the Company's distribution facilities or
businesses to distribute or dispense pharmaceuticals in such state;
changes in U.S. government policies (including reimbursement changes
arising from federal legislation, including the Medicare Modernization
Act and the Deficit Reduction Act of 2005); changes in regulatory or
clinical medical guidelines and/or reimbursement practices for the
pharmaceuticals we distribute, including erythropoiesis-stimulating
agents (ESAs) used to treat anemia patients; price inflation in
branded pharmaceuticals and price deflation in generics; fluctuations
in market interest rates; operational or control issues arising from
the Company's outsourcing of information technology activities;
success of integration, restructuring or systems initiatives;
fluctuations in the U.S. dollar - Canadian dollar exchange rate and
other foreign exchange rates; economic, business, competitive and/or
regulatory developments in Canada, the United Kingdom and elsewhere
outside of the United States; acquisition of businesses that do not
perform as we expect or that are difficult for us to integrate or
control; any disruption to or other adverse effects upon the PMSI
workers' compensation business caused by the Company's announcement
that it is pursuing the sale of PMSI; the inability of the Company to
successfully complete the sale of PMSI; the inability of the Company
to successfully complete any other transaction that the Company may
wish to pursue from time to time; changes in tax legislation or
adverse resolution of challenges to our tax positions; and other
economic, business, competitive, legal, tax, regulatory and/or
operational factors affecting the business of the Company generally.
Certain additional factors that management believes could cause actual
outcomes and results to differ materially from those described in
forward-looking statements are set forth (i) in Item 1A (Risk Factors)
in the Company's Annual Report on Form 10-K for the fiscal year ended
September 30, 2007 and elsewhere in that report and (ii) in other
reports filed by the Company pursuant to the Securities Exchange Act
of 1934.
CONTACT: AmerisourceBergen Corporation
Michael N. Kilpatric, 610-727-7118
mkilpatric@amerisourcebergen.com
SOURCE: AmerisourceBergen Corporation